Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2014

View Archived Issues

Scientists report on new method to generate engraftable hematopoietic stem cells

Pre-mRNA splice modifiers correct motor defects in spinal muscular atrophy

NIDA awards grant to support completion of phase IIa trial of ibudilast in opioid dependence

EMA approves pediatric investigation plan for TiGenix's Cx-601

First animal model of CLN7 disease described

Immunomedics patents new anti-histone H4 MAbs

Novel polypeptides patented by Circadian Technologies

Novel anti-HER2 antibodies divulged by LFB SA

CB2 agonists show potential for the treatment of kidney disease

Critical Outcome Technologies and MD Anderson Cancer Center sign letter of intent for COTI-2

Mast Therapeutics reports topline data from phase II study of AIR-001

Alferon and Ampligen to be tested against the Ebola virus

KemPharm begins human abuse liability and gastrointestinal motility trials of KP-201

Clinical data presented for ONO-6950 at the ERS meeting

Cirmtuzumab begins phase I testing for chronic lymphocytic leukemia

RoActemra receives E.U. approval for patients with early rheumatoid arthritis

OnCore Biopharma licenses cyclophilin inhibitors for HBV infection from NeuroVive

FDA approves IND application for MT-3724

Janssen and Johnson & Johnson form research collaboration with the University of Toronto

FDA approves two new indications for Epaned

VXc-486 and its prodrug as novel promising antibacterial candidates

Once-weekly Bydureon Pen launched in U.S. for adults with type 2 diabetes

Tesaro submits rolapitant NDA to FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.